JTJin Tao

Jin Tao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jin Tao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Anil A. Shah

    Division of Vascular Surgery, Department of Thoracic and Cardiovascular surgery, Allegheny Health Network, Pittsburgh, PA, USA

    1 shared publication
  • Haojing Zou

    Department of Cell Biology, University of Pittsburgh School of Medicine, 5117 Centre Avenue, Hillman Cancer Center, HCC2.6c, Pittsburgh, PA 15213 USA

    1 shared publication
  • Mingjing He

    Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, PR China

    1 shared publication
  • Qianming Chen

    Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Yong Wan

    Department of Pharmacology and Chemical Biology Emory University School of Medicine Atlanta GA 30322 USA

    1 shared publication
  • Zhuan Zhou

    Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

    1 shared publication

Latest Publications

  • Open Access

    The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics

    by Mingjing He, Zhuan Zhou, Anil A. Shah, Haojing Zou, Jin Tao, Qianming Chen, Yong Wan

    The addition of mono-ubiquitin or poly-ubiquitin chain to signaling proteins in response to DNA damage signal is thought to be a critical event that facilitates the recognition of DNA damage lesion site, the activation of checkpoint function, termination and checkpoint response and the recruitment of DNA repair proteins. Despite the ubiquitin modifiers, removal of ubiquitin from the functional proteins by the deubiquitinating enzymes (DUBs) plays an important role in orchestrating DNA damage response as well as DNA repair processes. Deregulated ubiquitination and deubiquitination could lead to genome instability that in turn causes tumorigenesis. Recent TCGA study has further revealed the connection between mutations in alteration of DUBs and various types of tumors. In addition, emerging drug design based on DUBs provides a new avenue for anti-cancer therapy. In this review, we will summarize the role of deubiquitination and specificity of DUBs, and highlight the recent discoveries of DUBs in the modulation of ubiquitin-mediated DNA damage response and DNA damage repair. We will furthermore discuss the DUBs involved in the tumorigenesis as well as interception of deubiquitination as a novel strategy for anti-cancer therapy.